Lupin Launches Dapaturn GM Range for Improved Approach to Manage Type 2 Diabetes
Global pharma major Lupin Limited announced the launch of Dapaturn GM Forte for the treatment of diabetic patients in India.
Lupin's Dapaturn GM™ Forte are fixed-dose combination (FDC) tablets that contain three powerful ingredients - Dapagliflozin, Glimepiride, and Metformin (Extended Release). These ingredients work together to lower blood sugar levels, prevent weight gain, and safeguard the heart and kidneys.
Dapagliflozin, an inhibitor of sodium-glucose co-transporter 2 (SGLT2), impedes the reabsorption of glucose in the kidneys, promoting its excretion in the urine. This helps to lower blood sugar levels and reduce the risk of kidney damage.
Glimepiride, a sulfonylurea, stimulates the pancreas to boost insulin production and lowers cell resistance to insulin. This dual action aids in lowering blood sugar levels and preventing diabetes-related complications.
Metformin, a biguanide, reduces glucose production in the liver and enhances cell sensitivity to insulin, effectively lowering blood sugar levels and preventing weight gain.
Dapaturn GM™ Forte FDCs have received approval from the Drug Controller General of India (DCGI), attesting to their safety and efficacy in the treatment of type 2 diabetes mellitus. They are available in two strengths:
- Dapaturn GM™ Forte contains Dapagliflozin 10 mg, Glimepiride 1 mg or 2 mg, and Metformin HCl 1000 mg ER.
What sets Lupin’s Dapaturn GM™ and Dapaturn GM™ Forte apart is the incorporation of a unique feature - the ‘Humrahi’ QR code. By scanning this code, users can gain access to ‘Humrahi’, an app and web-based patient support program providing personalized assistance to patients throughout their diabetes journey. This includes valuable tips, reminders, education, and motivation to help effective diabetes management.
Mr. Rajeev Sibal, President India Region Formulations, Lupin said, “With Dapaturn GM Range, we aim to provide our doctors and diabetic patients a powerful solution in a single pill, promising long-term benefits. We believe that the Dapaturn GM Range can significantly enhance the quality of life and self-assurance of diabetic patients in India.”
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Lupin Limited.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.